1 Protein-truncating variants in BSN are associated with severe adult-onset obesity,

2 type 2 diabetes and fatty liver disease

3 Yajie Zhao^{*1}, Maria Chukanova^{*2}, Katherine A Kentistou^{*1}, Zammy Fairhurst-Hunter³, Anna

4 Maria Siegert², Raina Jia¹, Georgina Dowsett², Eugene J Gardner¹, Felix R Day¹, Lena R

5 Kaisinger¹, Yi-Chun Loraine Tung², Brian Yee Hong Lam², Hsiao-Jou Cortina Chen², Quanli

6 Wang³, Jaime Berumen-Campos⁴, Pablo Kuri-Morales^{4,5}, Roberto Tapia-Conyer⁴, Jesus

- 7 Alegre-Diaz⁴, Jonathan Emberson⁶, Jason M Torres⁶, Rory Collins⁶, Danish Saleheen^{7,8},
- 8 Katherine R Smith³, Dirk S Paul³, Florian Merkle², Nick J Wareham¹, Slavé Petrovski³, Steve
- 9 O'Rahilly², Ken K Ong^{*1}, Giles S H Yeo^{*2} and John R B Perry^{*2,1}
- 10

11 Affiliations

- ¹MRC Epidemiology Unit, Wellcome-MRC Institute of Metabolic Science, University of
- 13 Cambridge School of Clinical Medicine, Cambridge CB2 0QQ, UK,

²Metabolic Research Laboratory, Wellcome-MRC Institute of Metabolic Science, University
 of Cambridge School of Clinical Medicine, Cambridge CB2 0QQ, UK,

³Centre for Genomics Research, Discovery Sciences, BioPharmaceuticals R&D,
 AstraZeneca, Cambridge, UK,

- ⁴Experimental Medicine Research Unit, Faculty of Medicine, National Autonomous
- 19 University of Mexico, Copilco Universidad, Coyoacán, 4360 Ciudad de México, Mexico,
- ⁵Instituto Tecnológico de Estudios Superiores de Monterrey, Av. Eugenio Garza Sada 2501
 Sur, Tecnológico, 64849 Monterrey, N.L., Mexico,
- ⁶Nuffield Department of Population Health, University of Oxford, Oxford OX3 7LF, England,
 UK,
- ⁷Center for Non-Communicable Diseases, Karachi, Sindh, Pakistan,
- ²⁵ ⁸Department of Medicine, Columbia University Irving Medical Center, New York, NY, USA
- 26
- 27 * denotes equal contribution
- 28 Correspondence to John R B Perry (John.Perry@mrc-epid.cam.ac.uk)

30 Abstract

31 Obesity is a major risk factor for many common diseases and has a significant heritable 32 component. While clinical and large-scale population studies have identified several genes 33 harbouring rare alleles with large effects on obesity risk, there are likely many unknown 34 genes with highly penetrant effects remaining. To this end, we performed whole exome-35 sequence analyses for adult body mass index (BMI) in up to 587,027 individuals. We 36 identified rare, loss of function variants in two genes – BSN and APBA1 – with effects on 37 BMI substantially larger than well-established obesity genes such as MC4R. One in ~6500 38 individuals carry a heterozygous protein truncating variant (PTV) in BSN, which confers a 39 6.6, 3.7 and 3-fold higher risk of severe obesity (BMI >40kg/m²), non-alcoholic fatty liver 40 disease and type 2 diabetes, respectively. In contrast to most other obesity-related genes, 41 rare variants in BSN and APBA1 had no apparent effect on childhood adiposity. 42 Furthermore, BSN PTVs magnified the influence of common genetic variants associated with 43 BMI, with a common polygenic score exhibiting an effect on BMI twice as large in BSN PTV 44 carriers than non-carriers. Finally, we explored the plasma proteomic signatures of BSN PTV 45 carriers as well as the functional consequences of BSN deletion in human iPSC-derived hypothalamic neurons. These approaches highlighted a network of differentially expressed 46 47 genes that were collectively enriched for genomic regions associated with BMI, and suggest 48 a role for degenerative neuronal synaptic function and neurotransmitter release in the 49 etiology of obesity.

51 Introduction

52 Over one billion people worldwide live with obesity, a global health challenge that is rapidly 53 increasing in scale^{1,2}. Obesity is the second leading cause of preventable death, increasing 54 the risks of diseases such as type 2 diabetes, cardiovascular disease and cancer^{1,3}. 55 Understanding the full range of social, psychological, and biological determinants of energy 56 intake and expenditure will be key to tackling this epidemic.

57 Early studies in mice highlighted the role of the leptin-melanocortin pathway in appetite and body weight regulation⁴, which led to candidate gene sequencing studies of rare individuals 58 59 with severe early-onset obesity. Those studies identified rare loss of function mutations in 60 key components of this pathway as causes of severe, early-onset obesity⁵, the most 61 common of which impact the melanocortin 4 receptor (MC4R)^{6,7}. In parallel, using a 'hypothesis-free' approach, large-scale population-based genome-wide association studies 62 63 (GWAS) have identified hundreds of common genetic variants associated with body mass index (BMI) in adults⁸. Those variants are mostly non-coding and are enriched near genes 64 expressed in the brain⁹. Individually, the effect of each variant is small, and cumulatively the 65 66 \sim 1000 common variants identified to date explain only \sim 6% of the population variance in 67 BMI⁸. The recent emergence of whole exome sequence (WES) data at the population scale has enabled exome-wide association studies (ExWAS), leading to a convergence of 68 69 common and rare variant discoveries. In a landmark study, Akbari et al used WES data in 70 ~640,000 individuals to identify rare protein-coding variants in 16 genes associated with 71 BMI¹⁰. These included genes with established roles in weight regulation (*MC4R*, *GIPR* and 72 PCSK1) in addition to novel targets, such as GPR75, in which loss-of-function mutations are 73 protective against obesity in humans and mice¹⁰. 74 The current study is an ExWAS for BMI using WES data of 419,668 UK Biobank

75 participants. Although this represents a subset of the exomes previously reported by Akbari 76 et al¹⁰, we were motivated by recent work demonstrating that in the context of gene-burden 77 analysis¹¹, the various choices around how one could define a qualifying rare variant can 78 highlight biologically relevant genes at exome-wide significance missed using alternative 79 definitions¹². Consistent with this, our approach identified novel rare variant associations with 80 BSN and APBA1, which we replicated in independent WES data from 167,359 individuals of non-European genetic ancestries. The detected rare protein truncating variants in BSN and 81 82 APBA1 have larger effects than other previously reported ExWAS genes¹⁰, and our findings 83 collectively suggest an emerging role for degenerative neuronal synaptic function and 84 neurotransmitter release in the etiology of obesity.

85

87 Results

88 To identify rare variants associated with adult BMI, we performed an ExWAS using genotype 89 and phenotype data from 419,668 individuals of European ancestry from the UK Biobank study¹³. Individual gene-burden tests were performed by collapsing rare (MAF<0.1%) 90 91 genetic variants across 18,658 protein-coding genes. We tested three categories of variants 92 based on their predicted functional impact: high-confidence Protein Truncating Variants 93 (PTVs), and two overlapping missense masks that used a REVEL¹⁴ score threshold of 0.5 or 94 0.7. This yielded a total of 37,691 gene tests with at least 30 informative rare allele carriers, 95 corresponding to a multiple-test corrected statistical significance threshold of $P < 1.33 \times 10^{-6}$

96 (0.05/37,691).

97 Genetic association testing was performed using BOLT-LMM¹⁵, which identified a total of

- nine genes meeting this threshold for significant association with adult BMI (Table S1). Our
- 99 gene-burden ExWAS appeared statistically well-calibrated, as indicated by low exome-wide
- test statistic inflation [λ_{GC} =1.05-1.15] and by the absence of significant associations with any
- 101 synonymous variant masks (Figure S1-2). Five of our identified associations were previously
- reported PTVs in *MC4R*, *UBR2*, *KIAA1109*, *SLTM* and *PCSK1*¹⁰. At the other four genes,
- heterozygous PTVs conferred higher risk for adult BMI: BSN (effect=3.05 kg/m², se=0.54,
- 104 $P=2x10^{-8}$, carrier N=65), TOX4 (3.61, se=0.71, $P=3.1x10^{-7}$, carrier N=39), APBA1 (2.08,
- 105 se=0.42, *P*=6.1x10⁻⁷, carrier N=111) and *ATP13A1* (1.82, se=0.37, *P*=1.1x10⁻⁶, carrier
- 106 N=139). For two of these genes, *BSN* and *ATP13A1*, we also found supporting evidence
- 107 from common genetic variants at the same locus associated with BMI (Figure S3) non-
- 108 coding alleles ~200kb upstream of BSN (rs9843653, MAF=0.49, beta=-0.13 kg/m²,
- 109 $P=9.5 \times 10^{-46}$) and 400kb upstream of ATP13A1 (rs72999063, MAF=0.16, beta=0.09 kg/m²,
- 110 $P= 3.2 \times 10^{-13}$, **Table S2**). Both of these GWAS signals were also associated with blood
- expression levels of *BSN* and *ATP13A1*, respectively¹⁶ (Table S2), and the BMI associations
- were replicated in independent GWAS data from the GIANT consortium⁹ (Figure S4, Table
- 113 **S2)**. We found no evidence of rare variant associations with BMI for any other genes at
- 114 these GWAS loci (Table S3).
- 115 We aimed to replicate our novel gene-burden rare variant associations in independent WES
- data from 167,359 individuals of non-European ancestry from the Mexico City Prospective
- 117 Study (MCPS)^{17,18} and the Pakistan Genomic Resource (PGR) study **(Table S4, Figure 1)**.
- 118 We observed supportive evidence for two of the four novel genes identified above 32 BSN
- 119 PTV carriers had a mean 2.8 kg/m² (se=0.84, P=9.4x10⁻⁴) higher BMI than non-carriers, and
- 120 20 APBA1 PTV carriers had a mean 2.33 kg/m² (se=1.05, *P*=0.03) higher BMI. These effect
- sizes were remarkably similar to those observed in UK Biobank (3.05 kg/m² and 2.08 kg/m²
- 122 for BSN and APBA1, respectively).

123 The effect of *BSN* is larger than any previously reported ExWAS gene on BMI (Figure 2),

and substantially increased the risks of obesity in UK Biobank; (BSN OR=3.04 [95%

125 confidence interval 1.87-4.94], *P*=7.7x10⁻⁶, 49% case prevalence; *APBA1* OR=2.14 [1.46-

126 3.13], *P*=8.5x10⁻⁵, 41% case prevalence) and for *BSN* also increased the risk of severe

127 obesity (OR=6.61 [3.01-14.55], *P*=2.6 x10⁻⁶, 11% case prevalence) but not for *APBA1*

128 (OR=1.91 [0.70-5.19], *P*=0.20, 4% case prevalence, **Figure 3**). Association statistics for

individual variants in *BSN* and *APBA1* in UK Biobank are shown in **Figure 1B** and **Table S5**.

130 The gene-level associations between *BSN* and *APBA1* and *BMI* were not driven by single

high-confidence (HC) PTVs (Table S6), and carriers appeared to be geographically

dispersed across the UK (Figure S5).

133 We next sought to understand the broader phenotypic profile of carriers of PTVs in BSN and APBA1. Both genes showed diverse associations with body composition, with higher fat and 134 135 lean mass across body compartments (Table S7), but no association with adult height 136 (P>0.05) or waist-to-hip ratio adjusted for BMI (P>0.05). In contrast to almost all previously 137 reported obesity-associated genes, neither BSN or APBA1 exhibited any association with 138 childhood body size or puberty timing (P>0.05), suggesting adult-onset effects on body 139 weight based on the phenotypes available in UK Biobank. In UK Biobank, carriers of PTVs in 140 BSN also had higher risk of type 2 diabetes (T2D) – BSN OR=3.03 (95% CI [1.60-5.76], P= 7.1x10⁻⁴, 18% case prevalence) – an effect size comparable to previously reported genes for 141

142 T2D^{19,20}. A broader phenome-wide analysis across 11,693 traits revealed a number of other

143 associations (Table S8); notably BSN PTV carriers had a substantially higher risk of non-

alcoholic fatty liver disease (NAFLD) - as defined by a Fatty Liver Index (FLI) $\ge 60^{21}$ or

145 Hepatic Steatosis Index (HSI) > 36²² – compared to non-carriers (OR=3.73 (95% CI [2.26-

146 6.16], *P*=8.4x10⁻⁷, 45% case prevalence).

147 Previous studies reported that common BMI-associated alleles did not modify the

penetrance of rare variants on BMI or obesity¹⁰. To evaluate whether this was true also for

149 BSN and APBA1, we created a common variant polygenic score (PGS) in UK Biobank, using

150 individual variant effect estimates obtained from independent GIANT consortium GWAS

data⁹. By testing the interaction between the PGS and rare variant carrier status in a linear

regression model, we observed significant effect modification by BSN PTVs (P= 0.01,

153 **Figure S6**), but not *APBA1* (*P*=0.22). Carriers of *BSN* PTVs showed double the effect size of

the PGS on BMI (0.6 BMI standard deviations per unit increase in PGS, equivalent to 2.9

155 kg/m²) than non-carriers (0.3 standard deviations, equivalent to 1.4 kg/m²).

156 To explore the putative biological mechanisms through which BSN and APBA1 might exert

their effects, we first characterized the plasma proteomic signature of PTV carriers using

158 Olink data on 1,463 circulating proteins available in ~50,000 UK Biobank participants^{23,24}.

159 We identified 6 and 17 PTV carriers with available proteomics data for BSN and APBA1,

160 respectively. No plasma proteins were associated with APBA1 carrier status after multiple-

161 test correction (P<3.42 x10⁻⁵ (0.05/1,463)), however BSN PTV carriers had higher levels of

- 162 lymphotoxin alpha (LT- α , previously known as TNF- β) than non-carriers (effect=1.07,
- 163 se=0.183, P=5.3x10⁻⁹) (Table S9). Furthermore, circulating LT- α levels were positively
- associated with BMI (1.18 kg/m² per 1 SD higher LT- α , *P*=7.6x10⁻¹²²) and common genetic
- variants at the LTA locus were associated with BMI (rs3130048, MAF=0.72, beta=-0.10

166 kg/m²/allele, $P=1.10x10^{-23}$). We repeated these analyses using the common BMI-associated

- variant (rs9843653) at BSN and identified 23 associated proteins, the most significant of
- which was Semaphorin-3F (-0.03 SD per BMI-increasing allele, *P*=6.7x10⁻⁴⁵), a member of
- the semaphorin family which has been previously implicated in obesity etiology²⁵. In total, 10
- of these 24 protein-encoded genes (including SEMA3F and LTA) were also implicated by
- 171 common variant signals for BMI (**Table S10**).

172 Finally, we explored the functional consequences of BSN deletion, which is highly expressed 173 in the brain, by generating CRISPR-Cas9 edited human iPSC hypothalamic neurons that 174 were heterozygous for BSN loss of function (Methods). Numbers of differentiated BSN^{+/-} cells were lower than WT cells (2,924 BSN^{+/-} and 18,010 WT); however, on visual inspection 175 176 there was no apparent morphological effect on neuronal differentiation (Figure S7). To 177 assess transcriptional differences between these cell populations, we performed single 178 nucleus RNAseq across all 20,934 hypothalamic cells differentiated from human iPSCs. A 179 UMAP plot of the cells identified eight distinct clusters (Figure S8), of which two clusters 180 (clusters 1 and 5, encompassing 4,991 cells) were enriched for *RBFOX3* (*NeuN*) expression, 181 a marker for mature neurons. These two clusters were also enriched for expression of BSN 182 and its binding partner Piccolo (PCLO), and were therefore separated and re-clustered for further analysis (Figure S8). This produced a further five clusters, including 2,712 WT and 183 184 343 BSN^{+/-} cells, which we selected for analysis of differential gene expression (defined by 185 corrected P<0.05 and Log₂FC > 1 or < -1). These analyses highlighted 251 differentiallyexpressed genes across one or more of the five clusters (**Table S11**), including genes with 186 187 established roles in obesity regulation, such as members of the semaphorin gene family²⁵ 188 and ALK^{26} . Pathway enrichment analyses across differentially-expressed genes highlighted 189 a number of biological processes (Table S12), with 'synapse organization' and 'negative 190 regulation of neuron projection development' the most significantly enriched pathways in 191 clusters 1 and 2, respectively. Collectively, differentially-expressed genes within these two 192 clusters (1 & 2) were also enriched for common variant associations with BMI (Table S13-193 14).

194 Discussion

We identified that rare PTVs in *APBA1* and *BSN* are associated with a substantial increase in adult BMI and higher risk of obesity in adults, but not in childhood. Rare PTVs in *BSN* were also found to be associated with higher risks for T2D and NAFLD. The associations with adult BMI were confirmed in independent cohorts and also supported by mapping of common variant signal to whole-blood eQTLs for *APBA1* and *BSN*.

200 APBA1 and BSN are among the few genetic determinants of adult-onset obesity. Although 201 childhood adiposity was assessed here by subjective recall, this trait is reported to show high 202 genetic correlation with measured childhood BMI and hence is a valid indicator for genetic 203 analyses²⁷. APBA1 encodes a neuronal adapter protein that interacts with the Alzheimer's 204 disease-associated gene amyloid precursor protein (APP). It has a putative role in signal 205 transduction as a vesicular trafficking protein with the potential to couple synaptic vesicle exocytosis to neuronal cell adhesion²⁸. BSN encodes Bassoon, a scaffolding protein 206 207 essential for the organization of the presynaptic cytoskeleton and for exocytosis-mediated 208 neurotransmitter release²⁹. Bsn knockout in mice reduces excitatory synaptic transmission 209 because vesicles are unable to efficiently fuse with the synaptic membrane³⁰. BSN is 210 expressed primarily in the brain and is reportedly upregulated in frontal lobes of patients with 211 multiple system atrophy, a progressive neurodegenerative disease³¹. Furthermore, rare 212 predicted-damaging missense mutations in BSN were reported in four patients with 213 progressive supranuclear palsy-like syndrome with features of multiple system atrophy and 214 Alzheimer's disease³². Hence, the links we identify here with adult-onset (rather than 215 childhood-onset) obesity may be consistent with the putative roles of APBA1 and BSN in 216 ageing-related neurosecretory vesicle dysfunction and neurodegenerative disorders. 217 Previous studies reported additive effects of common and rare susceptibility alleles on BMI¹⁰, 218 but no evidence for epistatic interactions that are indicative of biological interaction. Notably,

219 we found that carriers of rare PTVs in *BSN* showed enhanced susceptibility to the influence

of a common genetic polygenic risk score for adult BMI. The mechanistic basis for this

statistical interaction is unclear. However, as the common genetic susceptibility to obesity is

thought to act predominantly via the central regulation of food intake^{9,33}, we hypothesize that

BSN might have widespread involvement in the synaptic secretion of neurotransmitters thatsuppress appetite and increase satiety.

In conclusion, rare genetic disruption of *APBA1* and *BSN* have larger impacts on adult BMI
and obesity risk than heterozygous disruption of any other described obesity risk gene. Rare
PTVs in *APBA1* and *BSN* appear to preferentially confer risk to adult-onset obesity, which

- 228 we propose might be due to widespread vesicular dysfunction leading to reduced synaptic
- secretion of neurotransmitters that suppress food intake.
- 230

231 Figures



234

235 Figure 1 | Discovery and replication of novel rare variant associations with BMI in UK

Biobank. (a) Effect size estimates have been converted to kg/m². Extended data can be

found in Table S1 and S4. (b) Variant-level associations between HC PTVs in BSN and

APBA1 and BMI. The Y-axis shows trait increasing effects with a -1*log (10) p-value and trait

239 decreasing effects with a log(10) p-value. Dashed line denotes variants reaching a nominal

significance threshold P<0.05.



241 242

- Figure 2 | Comparison of effect between replicated associations and previously
- 244 **reported associations**¹⁰. The BMI effect size estimates are based on UK Biobank

245 participants only.



247



249 APBA1 or MC4R HC PTV carriers. The BMI categories are classified according to the

250 WHO's guidance.

252 Acknowledgements

253

Competing interests: Z. F.-H., Q.W., K.R.S, D.S.P., and S.P. are current employees and/or
 stockholders of AstraZeneca. J.R.B.P and E.G are employees and shareholders of Adrestia
 Therapeutics.

257

Funding: The MCPS has received funding from the Mexican Health Ministry, the National

- 259 Council of Science and Technology for Mexico, the Wellcome Trust (058299/Z/99), Cancer
- 260 Research UK, British Heart Foundation, and the UK Medical Research Council
- 261 (MC_UU_00017/2). These funding sources had no role in the design, conduct, or analysis of
- the study or the decision to submit the manuscript for publication.
- 263

264 We thank the participants and investigators in the UKB study who made this work possible

265 (Resource Application Number 26041; 9905) the UKB Exome Sequencing Consortium

266 (UKB-ESC) members AbbVie, Alnylam Pharmaceuticals, AstraZeneca, Biogen, Bristol-

- Myers Squibb, Pfizer, Regeneron and Takeda for funding the generation of the data; the
- 268 Regeneron Genetics Center for completing the sequencing and initial quality control of the
- 269 exome sequencing data; and the AstraZeneca Centre for Genomics Research Analytics and
- 270 Informatics team for processing and analysis of sequencing and phenotype data.
- 271

272 Data Accessibility

273

274 The UK Biobank phenotype and whole-exome sequencing data described here are publicly

available to registered researchers through the UKB data access protocol. Information about

276 registration for access to the data is available at: https://www.ukbiobank.ac.uk/enable-your-

277 <u>research/apply-for-access.</u> Data for this study were obtained under Resource Application

- 278 Numbers 26041 and 9905.
- 279

280 The Mexico City Prospective Study welcomes open access and collaboration data requests

from bona fide researchers. For more details on accessibility, the study's Data and Sample

282 Sharing policy may be downloaded (in English or Spanish) from

- 283 <u>https://www.ctsu.ox.ac.uk/research/mcps</u>. Available study data can be examined in detail
- through the study's Data Showcase, available at <u>https://datashare.ndph.ox.ac.uk/mexico/</u>.
- 285

286 Methods

287 UK biobank data processing and quality control

- 288 We employed the same processing strategies as outlined in our previous paper to analyse
- the whole-exome sequencing data and perform quality control steps¹⁹. We queried whole-
- 290 exome sequencing data from 454,787 individuals in the UK Biobank³⁴, excluding those with
- 291 excess heterozygosity, autosomal variant missingness on genotyping arrays >= 5%, or those
- not included in the subset of phased samples as defined by Bycroft et al¹³.
- 293 The whole-exome sequencing data was stored as population-level VCF files, aligned to
- GRCh38, and accessed through the UKBB RAP. In addition to the quality control measures
- already applied to the released data, which were described by Backman et al.³⁴, we
- 296 conducted several extra QC procedures. Firstly, we used 'bcftools norm' ³⁵ to split the
- 297 multiallelic sites and left-correct and normalise InDels. Next, we filtered out variants that
- failed our QC criteria, including: 1) read depth < 7, 2) genotype quality < 20, and 3) binomial
- 299 test p-value for alternate allele reads versus reference allele reads <= 0.001 for
- heterozygous genotypes. For InDel genotypes, we only kept variants with read depth >= 10
- and genotype quality >= 20. Variants that failed QC criteria were marked as missing (i.e., ./.).
- 302 After filtering, variants where more than 50% of genotypes were missing were excluded from
- 303 downstream analyses¹⁹.

304 The remaining variants underwent annotation using ENSEMBL Variant Effect Predictor

305 (VEP) v104³⁶ with the '-everything' flag, and additional plugins for REVEL¹⁴, CADD³⁷, and

306 LOFTEE³⁸. For each variant, a single ENSEMBL transcript was prioritised based on whether

- the annotated transcript was protein-coding, MANE select v0.97³⁹, or the VEP Canonical
- transcript. The individual consequence for each variant was then prioritised based on
- 309 severity as defined by VEP. Stop-gained, splice acceptor, and splice donor variants were
- 310 merged into a combined Protein Truncating Variant category, while annotations for missense
- and synonymous variants were adopted directly from VEP. We only included variants on
- autosomes and the X chromosome that were within ENSEMBL protein-coding transcripts
- and within transcripts included on the UKBB WES assay in our downstream analysis.

Our analyses focused primarily on individuals of European genetic ancestry, and we excluded those who withdrew consent from the study, resulting in a final cohort of 419,668 individuals.

317 Exome-wide gene burden testing in the UK Biobank

We used BOLT-LMM v2.3.6¹⁵ as our primary analytical tool to conduct the gene burden test.

- To run BOLT-LMM, we first queried a set of genotypes with MAC > 100 which derived from
- 320 the genotyping arrays for the individuals with the WES data to build the null model. To
- 321 accommodate BOLT-LMM's requirement for imputed genotyping data rather than per-gene
- 322 carrier status, we developed dummy genotype files where each gene was represented by a
- 323 single variant. We then coded individuals with a qualifying variant within a gene as
- heterozygous, regardless of the total number of variants they carried in that gene. We then
- 325 created the dummy genotypes for the MAF < 0.1% high confidence PTVs as defined by
- LOFTEE, missense variants with REVEL > 0.5 and missense variants with REVEL > 0.7. We
- then used BOLT-LMM to analyse phenotypes, using default parameters except for the
- inclusion of the 'ImmInfOnly' flag. In addition to the dummy genotypes, we also included all
- individual markers contained in WES data to generate the association test statistics for
- individual variants. We used age, age², sex, the first 10 principal components as calculated
- by Bycroft et al.¹³, and the WES released batch (50k, 200k, 450k) as covariates.
- To check whether there is a single variant driving the association, we performed a leave-
- one-out analysis for BSN and APBA1 using linear regression in R v3.6.3 by dropping the HC
- 334 PTV variants contained in our analysis one by one. In addition, we also checked the
- 335 geographic distribution of *APBA1* and *BSN* HC PTV carriers.

336 **Replication of the findings in two independent non-European cohorts**

- We tried to replicate our findings for the four novel genes in two independent non-European
 exome-sequenced cohorts: Mexico City Prospective Study (MCPS) and The Pakistan
 Genomic Resource (PGR) study.
- 340 Mexico City Prospective Study is a cohort study of 159,755 adults of predominantly Admixed
- American ancestry. Participants were recruited between 1998 and 2004 aged 35 years or
- 342 older from two adjacent urban districts of Mexico City. Phenotypic data were recorded during
- 343 household visits, including height, weight, and waist and hip circumferences. Disease history
- 344 was self-reported at baseline, and participants are linked to Mexican national mortality
- records. The cohort has been described in detail elsewhere^{17,18}. The MCPS study was
- 346 approved by the Mexican Ministry of Health, the Mexican National Council for Science and
- 347 Technology, and the University of Oxford.
- 348 The Pakistan Genomic Resource study has been recruiting participants aged 15-100 years
- 349 as cases or controls via clinical audits for specific conditions since 2005 from over 40
- 350 centres around Pakistan. Participants were recruited from clinics treating patients with
- 351 cardiometabolic, inflammatory, respiratory, or ophthalmological conditions. Information on

352 lifestyle habits, medical and medication history, family history of diseases, exposure to

smoking and tobacco consumption, physical activity, dietary habits, anthropometry, basic

blood biochemistry and ECG traits were recorded during clinic visits. DNA, serum, plasma,

355 and whole-blood samples were also collected from all study participants. The institutional

356 review board at the Center for Non-Communicable Diseases (IRB: 00007048,

357 IORG0005843, FWAS00014490) approved the study and all participants gave informed

358 consent.

Exome sequencing data for 141,046 MCPS and 37,800 PGR participants were generated at

the Regeneron Genetics Center and passed Regeneron's initial quality control (QC) that

361 included identifying sex discordance, contamination, unresolved duplicate sequences, and,

362 for MCPS, discordance with microarray genotype data. Genomic DNA underwent paired-end

363 75–base pair whole-exome sequencing at Regeneron Pharmaceuticals using the IDT xGen

364 v1 capture kit on the NovaSeq6000 platform. Conversion of sequencing data in BCL format

to FASTQ format and the assignments of paired-end sequence reads to samples were

based on 10-base barcodes, using bcl2fastq v2.19.0.

367 These exome sequences were processed at AstraZeneca from their unaligned FASTQ state.

368 A custom-built Amazon Web Services cloud computing platform running Illumina DRAGEN

Bio-IT Platform Germline Pipeline v3.0.7 was used to align the reads to the GRCh38

370 genome reference and perform single-nucleotide variant (SNV) and insertion and deletion

371 (indel) calling. SNVs and indels were annotated using SnpEff v4.3⁴⁰ against Ensembl Build

372 38.92. All variants were additionally annotated with their gnomAD MAFs (gnomAD v2.1.1

373 mapped to GRCh38)³⁸.

374

375 To further QC the sequence data, all MCPS and PGR exomes underwent a second screen

376 using AstraZeneca's bioinformatics pipeline which has been described in detail previously⁴¹.

Briefly, we excluded from analysis sequences that achieved a VerifyBamID freemix

378 (contamination) level of more than 4%, where inferred karyotypic sex did not match self-

379 reported gender, or where less than 94.5% of the consensus coding sequence (CCDS

release 22) achieved a minimum tenfold read depth. We further removed one individual from

every pair of genetic duplicates or monozygotic twins with a kinship coefficient > 0.45.

382 Kinship coefficients were estimated from exome genotypes using the --kinship function from

383 KING v2.2.3⁴². For MCPS we additionally excluded sequences with an average CCDS read

depth at least two standard deviations (SD) below the mean. After the above quality control

steps, there remained 139,603 (99.0%) MCPS and 37,727 (99.3%) PGR exomes.

In MCPS, we predicted the genetic ancestry of participants using PEDDY v0.4.2⁴³, with 1000

- 387 Genomes Project sequences as population references⁴⁴ and retain individuals with a
- predicted probability of Admixed American ancestry ≥ 0.95 who were within 4 SD of the
- 389 means for the top four principal components (PCs). In PGR we retained individuals with a
- predicted probability of South Asian ancestry \geq 0.95 who were within 4 SD of the means for
- the top four PCs. Following ancestry filtering, 137,059 (97.2%) MCPS and 36,280 (95.5%)
- 392 PGR exomes remained.
- 393 We assessed the association between BMI and weight quantitative traits with genotypes at
- the four proposed novel genes of interest using a previously described gene-level collapsing
- analysis framework, implementing a protein truncating variant (PTV) collapsing analysis
- 396 model⁴¹. We classified variants as PTVs if they had been annotated by SnpEff as:
- 397 exon_loss_variant, frameshift_variant, start_lost, stop_gained, stop_lost,
- 398 splice_acceptor_variant, splice_donor_variant, gene_fusion, bidirectional_gene_fusion,
- 399 rare_amino_acid_variant, and transcript_ablation.
- 400 We applied minor allele frequency filters to target rare variants; MAF < 0.001 in gnomAD
- 401 (overall and every population except OTH) and a leave-one-out MAF < 0.001 among our
- 402 combined case and control test cohort. For variants to qualify they had to also meet the
- 403 following QC filters: minimum site coverage 10X; annotation in CCDS transcripts (release
- 404 22); at least 80% alternate reads in homozygous genotypes; percent of alternate reads in
- heterozygous variants ≥ 0.25 and ≤ 0.8 ; binomial test of alternate allele proportion departure
- 406 from 50% in heterozygous state P > 1 × 10^{-6} ; GQ ≥ 20; FS ≤ 200 (indels) ≤ 60 (SNVs);
- 407 MQ \ge 40; QUAL \ge 30; read position rank sum score \ge -2; MQRS \ge -8; DRAGEN variant
- 408 status = PASS and <0.5% test cohort carrier QC failure. If the variant was observed in
- 409 gnomAD exomes, we also applied the filters: variant site achieved tenfold coverage in $\geq 25\%$
- 410 of gnomAD exomes; achieved exome z-score ≥ -2.0 ; exome MQ ≥ 30 and random forest
- 411 probability that the given variant is a true SNV or indel > 0.02 and > 0.01 respectively⁴⁵.
- 412 For the quantitative traits, and for each gene, the difference in mean between the carriers
- 413 and noncarriers of PTVs was determined by fitting a linear regression model, correcting for
- 414 age and sex. In addition to calculating individual statistics for MCPS and PGR, we also
- 415 meta-analysed the individual study effect sizes to generate a combined replication statistic
- 416 by using an inverse-variance fixed effect meta-analysis implemented in R using the rma.uni()
- 417 function from the package 'metafor' v3,8-1⁴⁶

418 Phenome-wide analysis in UKBB

- 419 We included binary and quantitative traits made available in the June 2022 UKB data
- release, harmonizing the phenotype data as previously described⁴¹. This resulted in 11,690

421 phenotypes for analysis; as available on <u>https://azphewas.com</u>. Based on clinical relevance
422 we derived an additional three phenotypes.

423 For the purposes of UKB phenome-wide analyses of the four putatively novel genes, the 424 same data generation and QC processes described for MCPS and PGR were applied to 425 UKB exomes. Following Regeneron and AstraZeneca QC steps, 445,570 UKB exomes 426 remained. The phenome-wide analysis was performed in UKB participants of predominately 427 EUR descent, whom we identified based on a PEDDY-derived predicted probability of 428 European ancestry ≥ 0.95 who were within 4 SD of the means for the top four PCs. Based 429 on the predicted ancestry pruning, 419,391 UKB exomes were included in the phenome-430 wide analyses of the four priority genes.

- 431 As described previously, we assessed the association between the 11,693 phenotypes with
- 432 genotypes at the four genes of interest, again using a PTV collapsing analysis model⁴¹,
- classifying variants as PTVs using the same SnpEff definitions as described for the MCPS
- 434 and PGR analysis. For variants to qualify for inclusion in the model, we applied the same
- 435 MAF and QC filters used in MCPS and PGR, with the exception that due to the larger
- sample size of UKB, only <0.01% of the test cohort carriers were permitted to fail QC.

437 Association testing for other anthropometry phenotypes and protein expression level.

438 We ran association tests between APBA1 and BSN HC PTV carriers and BMI-associated

439 common variant (rs9843653) at the BSN locus carriers and a list of anthropometry

- 440 phenotypes in R v3.6.3 (Table S5) including the same covariates we used in our exome-
- 441 wide gene burden tests. We acquired the normalised protein expression data generated by
- the Olink platform from the UKBB RAP^{23,24}. The detailed Olink proteomics assay, data
- 443 processing and quality control were described by Sun et al. ²³ For the association tests
- 444 between APBA1 and BSN PTV carriers and BMI-associated common variant (rs9843653) at
- the *BSN* locus carriers and 1,463 protein expression levels, we added age2, age*sex,
- 446 age^{2*}sex, Olink batch, UK Biobank centre, UK Biobank genetic array, number of proteins
- 447 measured and the first 20 genetic principal components (PCs) as covariates as suggested
- by Sun et al.²³ We chose the Bonferroni corrected p-value (P<3.42 x10⁻⁵ (0.05/1,463)) as the
- threshold for the significant associations.

450 BMI GWAS lookup and downstream analyses

- 451 Identified genes were queried for proximal BMI GWAS signals, using data from the UK
- Biobank, if within 500kb up- or downstream of the gene's start or end site. Any such signals
- 453 were further replicated in an independent BMI GWAS⁹.

454 We also performed colocalisation tests, using the Approximate Bayes Factor (ABF) method

455 in the R package "coloc" (version 5.1.0, 8) and blood gene expression level data from the

456 eQTLGen study¹⁶. Genomic regions were defined as ±500kb around each gene and loci

457 exhibiting an H4 posterior probability >0.5 were considered to show evidence of

458 colocalisation.

459 Finally, we also used the GWAS data to calculate gene-level common variant associations,

460 using MAGMA⁴⁷. To do this, we used all common but non-synonymous (coding) variants

461 within a given gene. Gene-level scores were further collapsed into pathway-level

462 associations where appropriate.

463 Interaction effect between PGS and PTV carrier status

To examine whether there is an interaction effect between the PTV carrier status of *BSN* and

465 APBA1, we included an interaction term between PGS and the carrier status of BSN and

466 *APBA1* PTVs in a linear regression adjusted for sex, age and age squared and the first 10

467 PCs.

468 The polygenic score (PGS) was constructed for 419,581 individuals of white European

- ancestry who had both genotype and exome sequencing data and a BMI record in the
- 470 UKBB. We used summary statistics of BMI from Locke et al.⁹, which included samples not in
- 471 the UKBB. Data was downloaded from the GIANT consortium. The summary statistics

included 2,113,400 SNPs with at least 50,0000 samples in a cohort of 322,154 participants

of European ancestry. For the genotype data of UKBB participants, a light quality check

474 procedure was applied, where SNPs were removed if they had a MAF <0.1%, HWE <1e-6 or

variants with more than 10% missingness genotypes. Additionally, SNPs that were

476 mismatched with those in the summary statistics (same rsID but different chromosome or

477 positions) were excluded. We used lassosum v4.0.5⁴⁸ to construct the PGS. The R squared

of the model including the PGS regressed on rank-based inverse normal transformed BMI

- 479 and adjusted for sex, age and age squared and the first 10 PCs as covariates was 11%.
- 480

481 Cell lines and routine cell culture

482

483 The KOLF2.1J human-induced pluripotent stem cell line and its derivatives⁴⁹ were

484 maintained on Geltrex (Thermo Fisher Scientific A1413202) coated plates in supplemented

485 StemFlex media (Thermo Fisher Scientific A3349401) with daily medium changes. For

486 passaging, the cells were washed with PBS and treated with TrypLE Express (Gibco,

487 12604021) at 37°C for 3 min. The cells were re-suspended in StemFlex media supplemented

488 with 10 µM ROCK Inhibitor Y-27632 dihydrochloride (Stemcell Technologies, 72304). ROCK

inhibitor was removed the following day with growth medium without the Y-27632. Unless

490 otherwise stated, cells were split at a 1:5 ratio. The absence of mycoplasma was confirmed

491 using an EZ-PCR Mycoplasma Test Kit (Biological Industries, 20-700-20) following the

492 manufacturer's instructions.

493

494 CRISPR-Cas9-mediated targeting of BSN

495

Two different small guide RNAs (sgRNA) with high predicted on-target and low predicted offtarget activity were designed using CRISPick

498 (<u>https://portals.broadinstitute.org/gppx/crispick/public</u>). For the production of sgRNAs, a 120

499 nucleotide oligo (Integrated DNA Technologies Inc.) including the SP6 promoter, sgRNA

500 sequences, and scaffold region were used as a template for synthesis by *in vitro*

transcription using the MEGAscript SP6 kit (Thermo Fisher, AM1330) as previously

502 described⁵⁰. The resulting sgRNAs were purified using the E.Z.N.A miRNA purification kit

503 (Omega Bio-tek, R7034-01), eluted in RNase-free water, and stored at -80°C. Since sgRNAs

vary in their efficacy, the relative cutting efficiencies of the two sgRNAs were tested in *in vitro*

505 cleavage assays as previously described⁵⁰. We selected the sgRNAs that showed activity at

the lowest Cas9 concentration for transfection into hPSC cells. Single-stranded

507 oligodeoxynucleotides (ssODN) templates (100bp) were constructed by IDT containing

target mutations in the middle and silent mutations within PAM sites. All sequences of the

509 primers, sgRNA, ssODN donors used in the study are listed in **(Table S15)**.

510

511 CRISPR-Cas9 ribonucleoprotein (RNP) complex-mediated editing in hESCs

512

513 To genetically edit the KOLF2.1J cells by homology-directed repair (HDR)^{51,52}, 3 µg purified 514 sgRNA was mixed with 4 µg of recombinant Cas9 nuclease (IDT 1081060) for 45 min at 515 room temperature to form stable ribonucleoprotein (RNP) complexes. The complex together 516 with 1µl of 100 µM ssODN was then transferred to a 20µl single-cell suspension of 2×10^5 517 hESCs in P3 nucleofection solution and electroporated using Amaxa 4D-Nucleofector™ 518 (Lonza) with program CA137. Transfected cells were seeded onto Geltrex-coated 24 well 519 plates containing a pre-warmed StemFlex medium containing Revitacell (100x, Gibco 520 A2644501) and Penicillin/Streptavidin (ThermoFisher Scientific, 15140-122). HDR enhancer 521 (IDT 1081072) was added to the cells at a 30μ M final concentration for each well. The 522 following day medium was changed to growth medium without Pen/Strep and Revitacell. To 523 increase HDR efficiency, cells were cultured under cold shock conditions (32°C at 5% CO₂ in 524 air atmosphere) for 48hr post transfection. Cells were given approximately 5-6 days to

- recover before single cells were then distributed into multiple Geltrex (1:40)-coated 96 well
- 526 plates by an Aria-Fusion sorter with a 100 μm nozzle. After ~2 weeks, viable clonally-derived
- 527 colonies were consolidated into duplicate 96 well plates to allow parallel cell
- 528 cryopreservation and genomic DNA extraction as previously described^{50,52}.
- 529

530 Generation and sequencing of pooled amplicons

531

532 Genomic DNA (gDNA) was extracted using HotShot buffer as previously described⁵⁰. The 533 target regions were amplified from gDNA using locus-specific primers to generate amplicons 534 approximately 150-200 bp in length. These "first-round" primers contained universal Fluidigm 535 linker sequences at their 5'-end with the following sequences: Forward primer: 5'-536 acactgacgacatggttctaca -3', Reverse primer: 5'- tacggtagcaggagacttggtct-3'. Specifically, 20 µl 537 PCR reactions were set up in 96 well plates using 0.5U Phusion Hot Start II High-Fidelity 538 DNA Polymerase (ThermoFisher Scientific, F-549L), 2 µl of extracted gDNA as template, 2 539 µI 5x GC buffer, 0.2 mM dNTPs, 2µM primers, and 3% DMSO, and run on the following 540 programme: 98°C 30sec, followed by 24 cycles of (95°C 10 sec, 72°C 20 sec/ decreased by 541 0.5°C per cycle, 72°C 15 sec) than 12 cycles of (98°C 10sec, 60°C 30 sec, 72°C 15 sec) 542 and 72°C 5 min. In the second round of PCR (indexing PCR), Fluidigm barcoding primers 543 were attached to the amplicons to uniquely identify each clone. 2 µl linker PCR product 544 diluted 1:10 was transferred to another 96-well PCR plate to perform this indexing PCR in 10 545 µl reactions containing 0.8 µM of Fluidigm barcoding primers, 2 µl 10x GC buffer, 0.2 mM 546 dNTPs 3% DMSO and 0.5U Phusion Hot Start II polymerase. The PCR programme was 547 95°C 2 min, 16 cycles of (95°C 20 sec, 60°C 20 sec, 72°C 25 sec), 72°C 3 min. For sequencing library preparation, barcoded PCR products were combined in equal proportion 548 549 based on estimation of band intensity on a 2% agarose gel, and the combined pool of PCR 550 products was purified in a single tube using Ampure XP beads (Invitrogen 123.21D) at 1:1 551 (V/V) to the pooled sample and eluted in 25 µl of water according to the manufacturer's 552 instructions. Library purity was confirmed by nanodrop, and final library concentration was 553 measured using the Agilent Bioanalyzer (High Sensitivity Kit, Agilent 5067-4626) and diluted 554 to 20 nM. Pooled libraries could be combined with other library pools adjusted to 20 nM, and 555 the resulting "superpool" volume was adjusted to a final volume of 20 µl before sequencing 556 which is performed by the Genomics Core, Cancer Research UK Cambridge Institute. 557 GenEditID platform⁵² was used for identification of the BSN P399X heterozygous and wild 558 type (WT) clones. 559

- 560
- 561

562 Hypothalamic neuron differentiation protocol

563

564 Gene edited BSN P399X heterozygous and WT clones were differentiated into 565 hypothalamic-like neurons as previously described^{53,54}. Briefly, cells were cultured overnight 566 on 10cm plate Geltrex coated plates (9.5 x10⁵ cells/well for 6-well plates) in Stemflex[™] with 567 10 µM ROCK inhibitor. Next day, neuroectoderm differentiation was initiated by dual SMAD 568 inhibition using XAV939 (Stemgent 04-1946), LDN 193289 (Stemgent 04-0074) and SB 569 431542 (Sigma Aldrich S4317) and Wnt signaling inhibition using XAV939 (Stemgent 04-570 1946) in an in-house neural differentiation N2B27 medium⁵⁴. From day 2 to day 7, cells were 571 directed 'towards ventral diencephalon' with Sonic hedgehog activation, by the addition of 572 Smoothened agonist SAG (1µM Thermo Fisher Scientific 56-666) and purmorphamine 573 (PMC, 1 µM Thermo Fisher Scientific 54-022), with SMAD and Wnt inhibition molecules 574 gradually replaced with N2 B27 medium changed every 2 days. At Day 8, the cells were switched into N2B27 with 5 µM DAPT (Sigma Aldrich D5942) to exit cell cycle. On Day 14, 575 the cells were harvested with TrypLETM supplemented with papain (Worthington LK003176) 576 577 and re-plated onto laminin-coated 6-well plates at a density of 3x10⁶ cells per well in the 578 presence of maturation medium containing brain-derived neurotrophic factor BDNF 579 (10ng/ml, Sigma) containing N2B27. On day 16 media was changed to Synaptojuice 1 580 (N2B27, 10ng/ml BDNF, 2 μM PD0332991 (Sigma Aldrich, PZ0199), 5 μM DAPT, 370 μM 581 CaCl₂ (Sigma Aldrich, 21115), 1 µM LM22A4 (Tocris, 4607), 2 µM CHIR99021 (Cell 582 Guidance Systems, SM13), 300 µM GABA (Tocris, 0344), 10 µM NKH447 (Sigma Aldrich, 583 N3290)). Cells were maintained in Synaptojuice 1 for a week before being changed to 584 Synaptojuice 2 (N2B27, 10ng/ml BDNF, 2 μM, 370 μM CaCl₂ 1 μM LM22A4, 2 μM 585 CHIR99021). Cells were then maintained in Synaptojuice 2 until day 36, with media renewal 586 every second day throughout the differentiation and maturation period.

587

588 Single nucleus RNA-sequencing

589

590 On day 36, cells were dissociated using TrypLE[™] and papain mixture, pelleted, and nuclei 591 were isolated following a 10x Genomics standardised protocol for single nucleus RNA Sequencing (NucSeq) as previously reported⁵⁵. Sequencing libraries for the 6 (3 x wild type 592 593 and 3 x BSN P399X Het) single-nuclei suspension samples were generated using 10X 594 Genomics Chromium Single-Cell 3' Reagent kits (Pleasanton, CA, USA, version 3) 595 according to the standardised protocol. Briefly, nuclear suspensions were loaded onto the 596 chromium chip along with gel beads, partitioning oil, and master mix to generate GEMs 597 containing free RNA. RNA from lysed nuclei was reverse transcribed and cDNA was PCR 598 amplified for 19 cycles. The amplified cDNA was used to generate a barcoded 3' library

according to the manufacturer's protocol, and paired-end sequencing was performed using
an Illumina NovaSeq 6000 (San Diego, CA, USA, read 1: 28 bp and read 2: 91 bp). Library
preparation and sequencing was performed by the Genomics Core, Cancer Research UK
Cambridge Institute.

603

604 Single-cell clustering and differential gene expression analysis.

605

606 For the 10X generated NucSeq datasets, Cellranger Version 6.0.1 was used to map 607 sequence reads to the human genome GRCh38 and perform the UMI and gene-level counts 608 against Ensembl gene model V100. The raw count matrices generated by the software were 609 then used for downstream analyses. A downstream analysis on the raw count matrices was 610 performed using the Seurat package version 4.0.3.56. Nuclei expressing less than 500 611 features, or less than 800 transcripts were removed as low-quality reads. Nuclei with more 612 than 10000 different features were removed as these were likely doublets. Any nuclei 613 expressing more than 5% mitochondrial RNA were excluded from the analysis. The 614 SCTransform package was used for normalization and variance stabilization of the data, 615 using regularized negative binomial regression⁵⁷. The data was integrated prior to PCA, 616 followed by unsupervised clustering analysis using the Louvain algorithm and Uniform 617 Manifold Approximation and Projection (UMAP) dimension reduction. Marker genes for each 618 cluster were identified using Wilcoxon's rank-sum test and receiver-operating curve (ROC) 619 analyses. Adjustment of p-values was performed using Bonferroni correction based on the 620 total number of genes in the dataset. Clusters with a high expression of a conventional 621 neuronal marker *RBFOX3* were separated into a new object and PCA, followed by 622 unsupervised clustering analysis using the Louvain algorithm and Uniform Manifold 623 Approximation and Projection (UMAP) dimension reduction was repeated. After that 624 differential expression of genes between nuclei from the wild type and BSN P399X Het 625 nuclei within each cluster was analysed using Negative Binomial GLM fitting and Wald statistics with the help of the DESeq2 package⁵⁸. The p-values attained by the Wald test 626 627 were corrected for multiple testing using the Benjamini and Hochberg method to generate 628 adjusted p-values. Genes with a Log2FC of <-1 or >1 and with a p-value adjusted < 0.05were selected for performing pathway analysis. The Metascape⁵⁹ pathway analysis was 629 630 used to identify pathways that were either upregulated or downregulated between the wild 631 type and BSN P399X Het nuclei. 632

- 633
-
- 634

635 References

- Blüher, M. Obesity: global epidemiology and pathogenesis. *Nature Reviews Endocrinology 2019 15:5* 15, 288–298 (2019).
- Health Effects of Overweight and Obesity in 195 Countries over 25 Years. *New England Journal of Medicine* 377, 13–27 (2017).
- Bi Cesare, M. *et al.* The epidemiological burden of obesity in childhood: A worldwide
 epidemic requiring urgent action. *BMC Med* 17, 1–20 (2019).
- 4. Zhang, Y. *et al.* Positional cloning of the mouse obese gene and its human
 homologue. *Nature* 372, 425–432 (1994).
- Loos, R. J. F. & Yeo, G. S. H. The genetics of obesity: from discovery to biology. *Nat Rev Genet* 23, 120–133 (2022).
- 64. Vaisse, C., Clement, K., Guy-Grand, B. & Froguel, P. A frameshift mutation in human
 MC4R is associated with a dominant form of obesity. *Nature Genetics 1998 20:2* 20,
 113–114 (1998).
- Yeo, G. S. H. *et al.* A frameshift mutation in MC4R associated with dominantly
 inherited human obesity. *Nature Genetics 1998 20:2* 20, 111–112 (1998).
- 8. Yengo, L. *et al.* Meta-analysis of genome-wide association studies for height and
 body mass index in ~700000 individuals of European ancestry. *Hum Mol Genet* 27,
 3641–3649 (2018).
- biology. *Nature 2015 518:7538* 518, 197–206 (2015).
- Akbari, P. *et al.* Sequencing of 640,000 exomes identifies GPR75 variants associated
 with protection from obesity. *Science (1979)* 373, (2021).
- Povysil, G. *et al.* Rare-variant collapsing analyses for complex traits: guidelines and applications. *Nature Reviews Genetics 2019 20:12* 20, 747–759 (2019).
- Stankovic, S. *et al.* Genetic susceptibility to earlier ovarian ageing increases de novo
 mutation rate in offspring. *medRxiv* 2022.06.23.22276698 (2022)
 doi:10.1101/2022.06.23.22276698.
- Bycroft, C. *et al.* The UK Biobank resource with deep phenotyping and genomic data. *Nature 2018 562:7726* 562, 203–209 (2018).
- Ioannidis, N. M. *et al.* REVEL: An Ensemble Method for Predicting the Pathogenicity
 of Rare Missense Variants. *Am J Hum Genet* **99**, 877–885 (2016).
- Loh, P. R. *et al.* Efficient Bayesian mixed-model analysis increases association power
 in large cohorts. *Nature Genetics 2015* 47:3 47, 284–290 (2015).
- 16. Võsa, U. *et al.* Large-scale cis- and trans-eQTL analyses identify thousands of genetic
 loci and polygenic scores that regulate blood gene expression. *Nature Genetics 2021*53:9 53, 1300–1310 (2021).
- Tapia-Conyer, R. *et al.* Cohort Profile: The Mexico City Prospective Study. *Int J Epidemiol* 35, 243–249 (2006).

674 675 676	18.	Ziyatdinov, A. <i>et al.</i> Genotyping, sequencing and analysis of 140,000 adults from the Mexico City Prospective Study. <i>bioRxiv</i> 2022.06.26.495014 (2022) doi:10.1101/2022.06.26.495014.
677 678	19.	Gardner, E. J. <i>et al.</i> Damaging missense variants in IGF1R implicate a role for IGF-1 resistance in the etiology of type 2 diabetes. <i>Cell Genomics</i> 2 , 100208 (2022).
679 680	20.	Zhao, Y. <i>et al.</i> GIGYF1 loss of function is associated with clonal mosaicism and adverse metabolic health. <i>Nature Communications</i> 2021 12:1 12 , 1–6 (2021).
681 682	21.	Bedogni, G. <i>et al.</i> The fatty liver index: A simple and accurate predictor of hepatic steatosis in the general population. <i>BMC Gastroenterol</i> 6 , 1–7 (2006).
683 684	22.	Lee, J. H. <i>et al.</i> Hepatic steatosis index: A simple screening tool reflecting nonalcoholic fatty liver disease. <i>Digestive and Liver Disease</i> 42 , 503–508 (2010).
685 686 687	23.	Sun, B. B. <i>et al.</i> Genetic regulation of the human plasma proteome in 54,306 UK Biobank participants. <i>bioRxiv</i> 2022.06.17.496443 (2022) doi:10.1101/2022.06.17.496443.
688 689 690	24.	Dhindsa, R. S. <i>et al.</i> Influences of rare protein-coding genetic variants on the human plasma proteome in 50,829 UK Biobank participants. <i>bioRxiv</i> 2022.10.09.511476 (2022) doi:10.1101/2022.10.09.511476.
691 692	25.	van der Klaauw, A. A. <i>et al.</i> Human Semaphorin 3 Variants Link Melanocortin Circuit Development and Energy Balance. <i>Cell</i> 176 , 729-742.e18 (2019).
693	26.	Orthofer, M. et al. Identification of ALK in Thinness. Cell 181, 1246-1262.e22 (2020).
694 695 696	27.	Richardson, T. G., Sanderson, E., Elsworth, B., Tilling, K. & Smith, G. D. Use of genetic variation to separate the effects of early and later life adiposity on disease risk: mendelian randomisation study. <i>BMJ</i> 369 , (2020).
697 698	28.	Butz, S., Okamoto, M. & Südhof, T. C. A tripartite protein complex with the potential to couple synaptic vesicle exocytosis to cell adhesion in brain. <i>Cell</i> 94 , 773–782 (1998).
699 700 701	29.	Tom Dieck, S. <i>et al.</i> Bassoon, a Novel Zinc-finger CAG/Glutamine-repeat Protein Selectively Localized at the Active Zone of Presynaptic Nerve Terminals. <i>Journal of Cell Biology</i> 142 , 499–509 (1998).
702 703	30.	Altrock, W. D. <i>et al.</i> Functional inactivation of a fraction of excitatory synapses in mice deficient for the active zone protein bassoon. <i>Neuron</i> 37 , 787–800 (2003).
704 705 706 707	31.	Hashida, H. <i>et al.</i> Cloning and Mapping of ZNF231, a Novel Brain-Specific Gene Encoding Neuronal Double Zinc Finger Protein Whose Expression Is Enhanced in a Neurodegenerative Disorder, Multiple System Atrophy (MSA). <i>Genomics</i> 54 , 50–58 (1998).
708 709 710	32.	Yabe, I. <i>et al.</i> Mutations in bassoon in individuals with familial and sporadic progressive supranuclear palsy-like syndrome. <i>Scientific Reports 2018 8:1</i> 8 , 1–13 (2018).
711 712	33.	De Lauzon-Guillain, B. <i>et al.</i> Mediation and modification of genetic susceptibility to obesity by eating behaviors. <i>Am J Clin Nutr</i> 106 , 996–1004 (2017).
713 714	34.	Backman, J. D. <i>et al.</i> Exome sequencing and analysis of 454,787 UK Biobank participants. <i>Nature 2021 599:7886</i> 599 , 628–634 (2021).

- 715 35. Danecek, P. *et al.* Twelve years of SAMtools and BCFtools. *Gigascience* 10, 1–4 (2021).
- McLaren, W. *et al.* The Ensembl Variant Effect Predictor. *Genome Biol* 17, 1–14 (2016).
- Rentzsch, P., Witten, D., Cooper, G. M., Shendure, J. & Kircher, M. CADD: predicting
 the deleteriousness of variants throughout the human genome. *Nucleic Acids Res* 47,
 D886–D894 (2019).
- 38. Karczewski, K. J. *et al.* The mutational constraint spectrum quantified from variation in
 141,456 humans. *Nature 2020 581:7809* 581, 434–443 (2020).
- Morales, J. *et al.* A joint NCBI and EMBL-EBI transcript set for clinical genomics and
 research. *Nature 2022 604*:7905 604, 310–315 (2022).
- Cingolani, P. *et al.* A program for annotating and predicting the effects of single
 nucleotide polymorphisms, SnpEff: SNPs in the genome of Drosophila melanogaster
 strain w1118; iso-2; iso-3. *Fly (Austin)* 6, 80–92 (2012).
- 41. Wang, Q. *et al.* Rare variant contribution to human disease in 281,104 UK Biobank
 exomes. *Nature 2021 597:7877 597*, 527–532 (2021).
- 42. Manichaikul, A. *et al.* Robust relationship inference in genome-wide association
 studies. *Bioinformatics* 26, 2867–2873 (2010).
- Pedersen, B. S. & Quinlan, A. R. Who's Who? Detecting and Resolving Sample
 Anomalies in Human DNA Sequencing Studies with Peddy. *Am J Hum Genet* 100, 406–413 (2017).
- Auton, A. *et al.* A global reference for human genetic variation. *Nature 2015 526:7571* **526**, 68–74 (2015).
- 45. Chen, S. *et al.* A genome-wide mutational constraint map quantified from variation in
 739 76,156 human genomes. *bioRxiv* 2022.03.20.485034 (2022)
 740 doi:10.1101/2022.03.20.485034.
- Viechtbauer, W. Conducting Meta-Analyses in R with the metafor Package. *J Stat Softw* 36, 1–48 (2010).
- de Leeuw, C. A., Mooij, J. M., Heskes, T. & Posthuma, D. MAGMA: Generalized
 Gene-Set Analysis of GWAS Data. *PLoS Comput Biol* 11, e1004219 (2015).
- Mak, T. S. H., Porsch, R. M., Choi, S. W., Zhou, X. & Sham, P. C. Polygenic scores
 via penalized regression on summary statistics. *Genet Epidemiol* 41, 469–480 (2017).
- Pantazis, C. B. *et al.* A reference human induced pluripotent stem cell line for largescale collaborative studies. *Cell Stem Cell* 29, 1685-1702.e22 (2022).
- 50. Santos, D. P., Kiskinis, E., Eggan, K. & Merkle, F. T. Comprehensive Protocols for
 CRISPR/Cas9-based Gene Editing in Human Pluripotent Stem Cells. *Curr Protoc Stem Cell Biol* 38, 5B.6.1-5B.6.60 (2016).
- 51. Skarnes, W. C., Pellegrino, E. & McDonough, J. A. Improving homology-directed
 repair efficiency in human stem cells. *Methods* 164–165, 18–28 (2019).

754 755 756	52.	Xue, Y. <i>et al.</i> GenEditID: an open-access platform for the high-throughput identification of CRISPR edited cell clones. <i>bioRxiv</i> 657650 (2019) doi:10.1101/657650.
757 758	53.	Merkle, F. T. <i>et al.</i> Generation of neuropeptidergic hypothalamic neurons from human pluripotent stem cells. <i>Development</i> 142 , 633–643 (2015).
759 760	54.	Kirwan, P., Jura, M. & Merkle, F. T. Generation and Characterization of Functional Human Hypothalamic Neurons. <i>Curr Protoc Neurosci</i> 81 , 3.33.1-3.33.24 (2017).
761 762	55.	Dowsett, G. K. C. <i>et al.</i> A survey of the mouse hindbrain in the fed and fasted states using single-nucleus RNA sequencing. <i>Mol Metab</i> 53 , 101240 (2021).
763 764 765	56.	Butler, A., Hoffman, P., Smibert, P., Papalexi, E. & Satija, R. Integrating single-cell transcriptomic data across different conditions, technologies, and species. <i>Nature Biotechnology 2018 36:5</i> 36 , 411–420 (2018).
766 767 768	57.	Hafemeister, C. & Satija, R. Normalization and variance stabilization of single-cell RNA-seq data using regularized negative binomial regression. <i>Genome Biol</i> 20 , 1–15 (2019).
769 770	58.	Love, M. I., Huber, W. & Anders, S. Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2. <i>Genome Biol</i> 15 , 1–21 (2014).
771 772	59.	Zhou, Y. <i>et al.</i> Metascape provides a biologist-oriented resource for the analysis of systems-level datasets. <i>Nature Communications 2019 10:1</i> 10 , 1–10 (2019).
773		